Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Patoulias, Dimitrios; Doumas, Michael

doi:10.3350/cmh.2020.0264

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study found that semaglutide resulted in significant declines in fat mass index and visceral adipose tissue, but not skeletal mass index, fat free mass index, and muscle strength [ 54 ]. However, further studies are needed on the use of these emerging novel therapies in lean or non-obese NAFLD patients [ 55 ].…”

Section: Lifestyle Intervention and Pharmacological Treatment In Non-...mentioning

confidence: 99%

Comparison between obese and non-obese nonalcoholic fatty liver disease

Chan

2023

Clin Mol Hepatol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver and is diagnosed following exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, it is associated with overnutrition and obesity, although it may also be found in lean or non-obese persons. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all-cause mortality, liver-related mortality and cardiovascular mortality among non-obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake and unaccounted weight changes over time.Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass increases and in the obese state. Overall, noninvasive tests, such as Fibrosis-4 index, NAFLD fibrosis score and liver stiffness measurement, perform better in lean or non-obese compared with obese NAFLD patients. Lifestyle intervention works in non-obese NAFLD patients and less amount of weight loss may be required to achieve similar results compared with obese NAFLD patients. Pharmacological therapy in non-obese NAFLD patients may require special consideration and a different approach compared with obese NAFLD patients.

show abstract

Section: Lifestyle Intervention and Pharmacological Treatment In Non-...mentioning

confidence: 99%

Comparison between obese and non-obese nonalcoholic fatty liver disease

Chan

2023

Clin Mol Hepatol

View full text Add to dashboard Cite

show abstract

“…Compared to healthy people, patients with lean NAFLD had higher metabolic syndrome occurrence, diastolic blood pressure, hemoglobin A1c, and insulin resistance [ 63 , 64 ]. Additionally, biochemical and hematologic markers, such as serum ALT, AST, Gamma glutamyl peptidase (γ-GT), and total bilirubin levels, were higher in patients with lean NAFLD than in healthy participants [ 60 , 61 , 63 ].…”

Section: Variants In Classification Of Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

Non-alcoholic fatty liver disease: Definition and subtypes

Han¹,

Baik²,

Kim³

2023

Clin Mol Hepatol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide, with a global prevalence of approximately 30%. However, the prevalence of NAFLD has been variously reported depending on the comorbidities. The rising prevalence of obesity in both the adult and pediatric populations is projected to consequently continue increasing NAFLD prevalence. It is a major cause of chronic liver disease worldwide, including cirrhosis and hepatocellular carcinoma (HCC). NAFLD has a variety of clinical phenotypes and heterogeneity due to the complexity of pathogenesis and clinical conditions of its occurrence, resulting in various clinical prognoses. In this article, we briefly described the basic definition of NAFLD and classified the subtypes based on current knowledge in this field.

show abstract

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Cited by 2 publications

References 8 publications

Comparison between obese and non-obese nonalcoholic fatty liver disease

Comparison between obese and non-obese nonalcoholic fatty liver disease

Non-alcoholic fatty liver disease: Definition and subtypes

Contact Info

Product

Resources

About